NRD
FULC icon

Nebula Research & Development’s Fulcrum Therapeutics FULC Stock Holding History

Nebula Research & Development’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,140
Closed -$353K – 1017
2024
Q4 		$353K Sell
75,140
-6,595
-8% -$24.3K 0.04% 672
2024
Q3 		$292K Buy
+81,735
New +$606K 0.03% 725

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's FULC Position: Q1 2025 in Review

Nebula Research & Development sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 75,140 shares — an estimated $353K sold.

Nebula Research & Development first reported a position in FULC in Q3 2024 and held it in 2 quarters. The position peaked at $353K in Q4 2024. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

  • Nebula Research & Development reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 75,140 Fulcrum Therapeutics shares in Q1 2025, an estimated $353K.
  • Nebula Research & Development first reported a position in Fulcrum Therapeutics in Q3 2024 and held it in 2 quarters.
  • Nebula Research & Development's Fulcrum Therapeutics position peaked at $353K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.